CMMB
Chemomab·NASDAQ
--
--(--)
--
--(--)
3.69 / 10
Netural
Fund flow evaluation is 7.39/10, reflecting robust money inflow despite adverse overall, block, small, medium, large, and extra-large trends. Analyst coverage is minimal (only one source, Jeff Jones from Oppenheimer, with a 0.0% historical win rate), leading to an overwhelmingly bullish consensus but low reliability. The sentiment is neutral, and investment conviction remains cautious.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-08-27
InstitutionOppenheimer
Times predicted2
Historical Win Rate0.0%
Is money flowing into or out of CMMB?
- CMMB holds a Bearish analyst rating, with 100% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 3.69/10 (Netural).
